Corbus (CRBP) prelim cash/investments ~$104.0M; cash $27.0M

Corbus Pharmaceuticals (CRBP) provided a preliminary financial update for the quarter ended September 30, 2025.

Accepted by SEC EDGAR 10/30/2025 - 04:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Corbus Pharmaceuticals (CRBP) provided a preliminary financial update for the quarter ended September 30, 2025. Management estimates cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025, including $27.0 million in cash and cash equivalents.

These figures are preliminary and unaudited, subject to normal closing procedures and potential adjustments. The company’s independent registered public accounting firm has not audited, reviewed, or compiled this data and offers no assurance. The estimate does not reflect any activity after September 30, 2025, including sales under the company’s Open Market Sale Agreement with Jefferies LLC, as amended. Corbus notes the estimate may change when final results are filed.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Corbus Pharmaceuticals (CRBP) disclose in its update?

Corbus estimated $104.0 million in cash, cash equivalents, and investments as of September 30, 2025, including $27.0 million in cash and cash equivalents.

Are the CRBP figures final or audited?

They are preliminary and unaudited, prepared by management, and may change after closing procedures and final adjustments.

Did the auditor review Corbus’s preliminary data?

No. The independent registered public accounting firm did not audit, review, or compile the preliminary figures and provides no assurance.

What period does the CRBP estimate cover?

The estimate is stated as of September 30, 2025 and pertains to the quarter ended on that date.

Does the estimate include post-quarter ATM sales by Corbus?

No. It does not reflect any sales after September 30, 2025 under the Open Market Sale Agreement with Jefferies LLC, as amended.

What components are included in the $104.0 million figure?

It includes cash, cash equivalents, and investments, with $27.0 million specifically in cash and cash equivalents.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001595097false00015950972025-10-302025-10-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2025

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37348	46-4348039
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
500 River Ridge Drive
Norwood, Massachusetts				02062
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CRBP		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Financial Update and Preliminary Financial Information for the Quarter Ended September 30, 2025

Corbus Pharmaceuticals Holdings, Inc. (the “Company”) has not finalized its financial statements as of and for the quarter ended September 30, 2025. Based on its current estimates, the Company expects to report that it had cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025, which includes $27.0 million in cash and cash equivalents. The actual amounts that the Company will report will be subject to its financial closing procedures and any final adjustments that may be made prior to the time its financial results for the quarter ended September 30, 2025 are finalized and filed with the U.S. Securities and Exchange Commission. The preliminary financial data included herein has been prepared by, and is the responsibility of, management. The Company’s independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data and, accordingly, does not express an opinion or any other form of assurance with respect thereto. This estimate should not be viewed as a substitute for financial statements prepared in accordance with accounting principles generally accepted in the United States. It does not reflect any updates following September 30, 2025, including any sales made under the Open Market Sale Agreement, dated August 6, 2020, by and between the Company and Jefferies LLC, as amended, following such date, or consider any events or circumstances after the date that it was prepared, and is not necessarily indicative of the results to be achieved in any future period. Accordingly, you should not place undue reliance on this preliminary estimate. The Company assumes no duty to update this preliminary estimate except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Corbus Pharmaceuticals Holdings, Inc.
Date:	October 30, 2025	By:	/s/ Yuval Cohen
			Name: Yuval Cohen Title: Chief Executive Officer